Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.63 |
| ▸ | MAP2K2 | P36507 | 8/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ACTR3 | P61158 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348377 | 0.92 | MAP2K1 (0.65) | MAP2K1MAP2K2 | |
| SCHEMBL696722 | 0.90 | MAP2K1 (0.51) | MAP2K1 | |
| SCHEMBL697713 | 0.82 | MAP2K1 (0.53) | MAP2K1 | |
| SCHEMBL696855 | 0.82 | MAP2K1 (0.70) | MAP2K1MAP2K2 | |
| SCHEMBL696775 | 0.81 | MAP2K1 (0.61) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL696783 | 0.81 | MAP2K1 (0.72) | MAP2K1MAP2K2 | |
| SCHEMBL2432192 | 0.79 | MAP2K1 (0.71) | MAP2K1MAP2K2 | |
| SCHEMBL12299245 | 0.79 | MAP2K1 (0.64) | MAP2K1MAP2K2 | |
| SCHEMBL697484 | 0.78 | MAP2K1 (0.79) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL2427808 | 0.78 | MAP2K1 (0.63) | MAP2K1MAP2K2CHRM2CHRM1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | claimed |
| EP-2421612-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | Novartis AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NRAS, BRAF, MAP3K1 | MAP2K1 48/4885MAP2K2 38/4885PIM1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.